Results 211 to 220 of about 2,781,261 (274)

Cholinesterase Inhibitors and Beyond

Current Alzheimer Research, 2009
Cholinesterase inhibitors (ChEIs) were introduced in the therapy of Alzheimer Disease (AD) in the nineteen nineties with great expectations. The hopes and large interest raised by these drugs are well demonstrated by 12,000 references listed by PubMed under 'ChEI' for 1995-2007. The list is reduced to 2500 if we confine ourselves to 'ChEIs and dementia'
PEPEU, GIANCARLO, GIOVANNINI, MARIA GRAZIA   +1 more
openaire   +2 more sources

Cholinesterase inhibitors and memory

Chemico-Biological Interactions, 2010
A consensus exists that cholinesterase inhibitors (ChEIs) are efficacious for mild to moderate Alzheimer's Disease (AD). Unfortunately, the number of non-responders is large and the therapeutic effect is usually short-lasting. In experimental animals, ChEIs exert three main actions: inhibit cholinesterase (ChE), increase extracellular levels of brain ...
PEPEU, GIANCARLO, GIOVANNINI, MARIA GRAZIA   +1 more
openaire   +4 more sources

Drug Interactions with Cholinesterase Inhibitors [PDF]

Drugs & Aging, 2003
Cholinesterase inhibitors are used for the symptomatic treatment of patients with Alzheimer's disease. This population often has numerous comorbidities and receives treatment with multiple medications. The astute clinician should remain mindful of possible drug interactions, both pharmacokinetic and pharmacodynamic, that may occur with concomitant ...
M. Lynn Crismon, Jennifer L. Defilippi
openaire   +2 more sources

Effect of cholinesterase inhibitors on attention

Chemico-Biological Interactions, 2013
Advantages and limits of the use of cholinesterase inhibitors (ChEI) in Alzheimer's disease (AD) are well established. Their effects result from an increase in extracellular acetylcholine (ACh) whose hydrolysis is prevented by cholinesterase inhibition. In this way, the cholinergic deficit which characterizes AD may be corrected.
Giancarlo Pepeu, GIOVANNINI, MARIA GRAZIA, Laura Bracco   +2 more
openaire   +3 more sources

The Cholinesterase Inhibitors

Journal of Psychiatric Practice, 2003
Dementia is a serious and growing problem that presents enormous burdens to patients, their families, and national healthcare systems throughout the world. In the United States, there are currently two classes of psychopharmacologic agents approved for the treatment of Alzheimer's disease: the cholinesterase inhibitors, which are approved for use in ...
openaire   +3 more sources

Sex and Gender Differences in the Brain Cholinergic System and in the Response to Therapy of Alzheimer Disease with Cholinesterase Inhibitors.

Current Alzheimer Research, 2018
This review has two aims. First, to examine whether or not sex and gender may influence the brain cholinergic system in animals and in humans. Second, to examine the available evidence of sexually dimorphic response to the therapeutic and toxic effects ...
E. Giacobini, G. Pepeu
semanticscholar   +1 more source

Cholinesterases and Cholinesterase Inhibitors

Archives of Neurology, 2001
1. Introduction 2. Cholinesterase Inhibitors: An Introduction 3. Molecular Structure of Cholinesterases and Complexes with Inhibitors 4. Rational Design of Cholinesterase Inhibitors 5. Genetics and Epigenetics of Mammalian Cholinesterases 6. The Gene Structure of Cholinesterases 7. Molecular Forms and Anchoring of Cholinesterases 8. Mechanism of Action
openaire   +2 more sources

Clinical Pharmacokinetics of Cholinesterase Inhibitors

Clinical Pharmacokinetics, 1986
This review deals mainly with the pharmacokinetics of the reversible quaternary cholinesterase inhibitors neostigmine, pyridostigmine and edrophonium, which are mainly used to antagonise non-depolarising neuromuscular blockade in general anaesthesia and in the symptomatic treatment of myasthenia gravis.
Sten-Magnus Aquilonius, Per Hartvig
openaire   +3 more sources

A New Series of Cholinesterase Inhibitors*

Journal of the American Pharmaceutical Association (Scientific ed.), 1954
In a series of bis onium biphepyl derivatives, alteration of substitutions on the quaternary nitrogen produced a wide variation in toxicity and ability to inhibit cholinesterase, as well as other pharmacological responses. Three members of this series were found to be equal to neostigmine bromide as inhibitors of bovine erythrocyte cholinesterase ...
John P. Long, F.W. Schueler
openaire   +3 more sources

Cardiovascular Outcomes of Cholinesterase Inhibitors in Individuals with Dementia: A Meta‐Analysis and Systematic Review

Journal of The American Geriatrics Society, 2018
To evaluate the cardiovascular (CV) effects of acetylcholinesterase inhibitors (AChEIs) in individuals with ...
A. Işık, P. Soysal, B. Stubbs, M. Solmi, C. Basso, S. Maggi, P. Schofield, N. Veronese, C. Mueller   +8 more
semanticscholar   +1 more source